Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 10, 2026 | −$0.78 | — | $243.68M | +120.4% | −$0.58 |
| Q1 FY26ended Mar 31, 2026 | May 7, 2026 | −$0.84 | — | $194.52M | +66.8% | −$0.70 |
| Q4 FY25ended Dec 31, 2025 | — | −$1.00 | — | $154.18M | +2521.2% | — |
| Q3 FY25ended Sep 30, 2025 | — | −$0.95 | — | $120.70M | +4318.0% | — |
| Q2 FY25ended Jun 30, 2025 | — | −$0.95 | — | $110.57M | +4999.9% | — |
| Q1 FY25ended Mar 31, 2025 | — | −$0.88 | — | $116.63M | −44.8% | — |
| Q4 FY24ended Dec 31, 2024 | — | −$1.40 | — | $5.88M | +237.1% | — |
| Q3 FY24ended Sep 30, 2024 | — | −$0.86 | — | $2.73M | −33.2% | — |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe BridgeBio Pharma shares, not any token. As of Aug 10, 2026, from Massive's standardised financials and the earnings calendar.
| Q2 FY24ended Jun 30, 2024 |
| — |
| −$0.39 |
| — |
| $2.17M |
| — |
| — |
| Q1 FY24ended Mar 31, 2024 | — | −$0.20 | — | $211.12M | — | — |
| Q4 FY23ended Dec 31, 2023 | — | −$0.96 | — | $1.75M | — | — |
| Q3 FY23ended Sep 30, 2023 | — | −$1.08 | — | $4.09M | — | — |